Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.
Berruti A, Bitossi R, Gorzegno G, Bottini A, Generali D, Milani M, Katsaros D, Rigault de la Longrais IA, Bellino R, Donadio M, Ardine M, Bertetto O, Danese S, Sarobba MG, Farris A, Lorusso V, Dogliotti L. Berruti A, et al. Among authors: danese s. Br J Cancer. 2005 Feb 28;92(4):634-8. doi: 10.1038/sj.bjc.6602335. Br J Cancer. 2005. PMID: 15668714 Free PMC article. Clinical Trial.
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.
Donadio M, Manzin E, Berruti A, Bottini A, Gorzegno G, Danese S, DeFabiani E, Sarobba MG, Lorusso V, Castiglione F, Moro G, Bertetto O, Bumma C, Dogliotti L. Donadio M, et al. Among authors: danese s. Cancer Chemother Pharmacol. 2001 May;47(5):391-6. doi: 10.1007/s002800000247. Cancer Chemother Pharmacol. 2001. PMID: 11391853 Clinical Trial.
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L; Epirubicin-Lonidamine Group, Orbassano, Torino, Italy. Berruti A, et al. Among authors: danese s. J Clin Oncol. 2002 Oct 15;20(20):4150-9. doi: 10.1200/JCO.2002.08.012. J Clin Oncol. 2002. PMID: 12377958 Clinical Trial.
Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
Berruti A, Bitossi R, Bottini A, Bonardi S, Donadio M, Nigro C, Bertetto O, Danese S, Bertone E, Sarobba MG, Farris A, Katsaros D, Castiglione F, Volpe T, Lattuada S, Mancarella S, Dogliotti L. Berruti A, et al. Among authors: danese s. Eur J Cancer. 2005 Jan;41(2):249-55. doi: 10.1016/j.ejca.2004.07.003. Eur J Cancer. 2005. PMID: 15661550 Clinical Trial.
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Lombardi AV, Manzione L, Cartenì G, Nardi M, Danese S, Valerio MR, de Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F. Pignata S, et al. Among authors: danese s. BMC Cancer. 2006 Jan 7;6:5. doi: 10.1186/1471-2407-6-5. BMC Cancer. 2006. PMID: 16398939 Free PMC article. Clinical Trial.
1,206 results